Boehringer continues fibrosis drive via acquisition of Enleofen assets

The acquisition of Enleofen’s preclinical IL-11 inhibition platform is the latest in a string of deals by Boehringer to build out its fibrosis tool kit, giving the German pharma therapies against a new target for the indication.

Enleofen Bio Pte. Ltd. is eligible for more than $1 billion per product from Boehringer Ingelheim GmbH

Read the full 535 word article

User Sign In